Abstract
The pharmacokinetics and pharmacodynamics of adinazolam were studied in 15 normal, healthy, non-obse volunteers. Placebo capsules and capsules containing 20, 40, and 60 mg adinazolam mesylate were administered as single oral doses in a randomized, 4-way crossover design. Plasma concentrations of adinazolam and mono-N-desmethyladinazolam (NDMAD) were determined by HPLC. Psychomotor performance and memory tests were performed and the degree of sedation assessed at designated times following drug administration. Adinazolam and NDMAD pharmacokinetics were linear throughout the dosage range studied. The ratio of NDMAD to adinazolam area under the curve was approximately 4:1. Dose-related decrements in psychomotor performance and memory were observed up to 8h after dosing (P<0.025 in all cases). Psychomotor performance decrements correlated more closely with NDMAD plasma concentrations than with adinazolam concentrations. These results suggest that NDMAD is responsible for a significant degree of the sedative and psychomotor effects observed after the administration of adinazolam.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amsterdam JD, Kaplan M, Potter L, Bloom L, Rickels K (1986) Adinazolam, a new triazolobenzodiazepine, and imipramine in the treatment of major depressive disorder. Psychopharmacology 88:484–488
Dunner D, Myers J, Khan A, Avery D, Ishiki D, Pyke R (1987) Adinazolam — a new antidepressant: findings of a placebocontrolled, double-blind study in outpatients with major depression. J Clin Psychopharmacol 7:170–172
Fleishaker JC, Phillips JP, Smith TC, Smith RB (1989) Multiple dose pharmacokinetics and pharmacodynamics of adinazolam in elderly subjects. Pharm Res (in press)
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd ed. Dekker, New York
Kroboth PD, Smith RB, Erb RJ (1988) Tolerance to alprazolam after intravenous bolus and continuous infusion: psychomotor and EEG effects. Clin Pharmacol Ther 43:270–277
Lahti A, Sethy VH, Barsuhn C, Hester JB (1983) Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology 22:1277–1282
Peng GW, Todd WM, Rykert UM, Stryd RP, Pyke RE (1986) Dose proportionality of adinazolam mesylate (Deracyn®). Pharm Res [Suppl]3:108s
Randt CT, Brown ER (1983) Randt memory test administration manual. Life Science Associates, Bayport, New York
Sethy VH, Collins RJ, Daniels EG (1984) Determination of biological activity of adinazolam and its metabolites. J Pharm Pharmacol 36:546–548
Sethy VH, Francis JW, Day JS (1986) The effect of proadifen on the metabolism of adinazolam. J Pharm Pharmacol 38:631–632
Smith RB, Kroboth PD (1987) Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacology 93:105–112
Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP (1984) Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 84:452–456
Smith RB, Kroboth PD, Varner PD (1987) Pharmacodynamics of triazolam after intravenous administration. J Clin Pharmacol 27:971–979
Wagner JG, Rogge MC, Natale RB, Albert KS, Szpunar GJ (1987) Single dose and steady-state pharmacokinetics of adinazolam after oral administration to man. Biopharm Drug Dispos 8:405–425
Wechsler D (1955) A manual for the Wechsler Adult Intelligence Scale. Psychological Corporation, New York
Weiss M (1988) A general model of metabolite kinetics following intravenous and oral administration of the parent drug. Biopharm Drug Dispos 9:159–176
Ziegler WH, Schalch E, Leishman B, Eckert M (1980) Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites. Br J Clin Pharmacol 16:63S-69S
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fleishaker, J.C., Phillips, J.P. Adinazolam pharmacokinetics and behavioral effects following administration of 20–60 mg oral doses of its mesylate salt in healthy volunteers. Psychopharmacology 99, 34–39 (1989). https://doi.org/10.1007/BF00634449
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00634449